- Home
- SGMO vs UCL Comparison
SGMO vs UCL Comparison
Compare SGMO & UCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMO
- UCL
- Stock Information
- Founded
- SGMO 1995
- UCL 2014
- Country
- SGMO United States
- UCL Hong Kong
- Employees
- SGMO N/A
- UCL N/A
- Industry
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- UCL Telecommunications Equipment
- Sector
- SGMO Health Care
- UCL Consumer Discretionary
- Exchange
- SGMO Nasdaq
- UCL Nasdaq
- Market Cap
- SGMO 122.8M
- UCL 144.5M
- IPO Year
- SGMO 2000
- UCL 2020
- Fundamental
- Price
- SGMO $0.58
- UCL $3.91
- Analyst Decision
- SGMO Buy
- UCL
- Analyst Count
- SGMO 6
- UCL 0
- Target Price
- SGMO $4.50
- UCL N/A
- AVG Volume (30 Days)
- SGMO 7.8M
- UCL 238.7K
- Earning Date
- SGMO 08-07-2025
- UCL 08-13-2025
- Dividend Yield
- SGMO N/A
- UCL N/A
- EPS Growth
- SGMO N/A
- UCL N/A
- EPS
- SGMO N/A
- UCL 0.02
- Revenue
- SGMO $81,706,000.00
- UCL $89,277,000.00
- Revenue This Year
- SGMO $1.29
- UCL $6.09
- Revenue Next Year
- SGMO $1.60
- UCL $7.01
- P/E Ratio
- SGMO N/A
- UCL $169.37
- Revenue Growth
- SGMO 565.52
- UCL 3.72
- 52 Week Low
- SGMO $0.41
- UCL $0.80
- 52 Week High
- SGMO $3.18
- UCL $4.19
- Technical
- Relative Strength Index (RSI)
- SGMO 58.57
- UCL 74.41
- Support Level
- SGMO $0.50
- UCL $3.15
- Resistance Level
- SGMO $0.58
- UCL $4.10
- Average True Range (ATR)
- SGMO 0.05
- UCL 0.40
- MACD
- SGMO 0.00
- UCL 0.10
- Stochastic Oscillator
- SGMO 84.21
- UCL 85.03
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.